

Topical Collection

COVID-19 Vaccine Development and Vaccination

Message from the Collection Editors

Dear Associates, There are >200 vaccine candidates for COVID-19 being developed. Of these, >50 candidate vaccines are in clinical trials. It is expected that the different vaccines in development will secure the chance that one or more will be efficacious and safe. There are three approaches to vaccine design: (1) whole virus, (2) part of the virus that triggers immunity, or (3) viral genetic material. This Collection on "COVID-19 Vaccine Development and Vaccination" will highlight the recent effort to develop, test, and use vaccines on individuals with promising vaccine platforms against SARS-CoV-2. These approaches may include a whole virus approach (live-attenuated vaccine, inactivated vaccine, or viral vector vaccine), a subunit approach, or genetic approaches that include nucleic acid vaccines. Dr. Steven B. Bradfute



Collection Editors

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, University of Georgia, Athens, GA 30602, USA

Dr. Scott Anthony

National Institute of Allergy and Infectious Diseases (NIAID), Frederick, MD, USA



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/73952

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).